DelveInsight's "TEPMETKO Market Size, Forecast, and Market Insight Report" highlights the details around TEPMETKO, a kinase ...

Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta ...

With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...

It is the first cMET inhibitor to reach the market in China, ahead of rival therapies such as Novartis/Incyte's Tabrecta (capmatinib) and Merck KGaA's Tepmetko (tepotinib), which have both been ...

Analysts' assessment points toward 'Royalty revenues- Tabrecta' reaching $6.27 million. The estimate indicates a year-over-year change of +34.1%. The consensus estimate for 'Royalty revenues ...

Incyte also receives royalties from the sales of Tabrecta (capmatinib) for the treatment of adult patients with metastatic non-small-cell lung cancer. Its partner, NVS, has exclusive worldwide ...

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging ...

After hours: March 6 at 4:35:57 p.m. EST Loading Chart for INCY ...